Drugs / Vebeglogene autotemcel
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06308159 | May 2024 → Aug 2027 expected | beta thalassemia | Lantu Biopharma | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vebeglogene autotemcel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06308159 ↗ |
| Action | Restore | “carrying the functional HBB gene” NCT06308159 ↗ |
| Target | HBB | “encoding functional HBB gene” NCT06308159 ↗ |